Clinical Monograph: OxyContin 20 mg (Oxycodone HCl Extended-Release)

OxyContin 20 mg controlled-release packaging. Source: OIDA Image Collection – Johns Hopkins University

1. Classification and Chemical Overview

Oxycodone is a semi-synthetic, pure opioid agonist derived from the opium alkaloid thebaine. Chemically designated as (5$\alpha$)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride, it belongs to the phenanthrene derivative class. Under the Anatomical Therapeutic Chemical (ATC) classification system, oxycodone is indexed under N02AA05.

OxyContin 20 mg is formulated as an extended-release (prolonged-release) film-coated tablet containing 20 mg of oxycodone hydrochloride (equivalent to 17.93 mg free oxycodone base). Modern formulations incorporate abuse-deterrent properties designed to resist crushing, breaking, or dissolving into a injectable gel. Globally, OxyContin is classified as a strictly controlled substance (e.g., Schedule II under the US Controlled Substances Act; Class B / Schedule 2 Controlled Drug in the UK) and is available strictly as a Prescription Only Medicine (POM).

2. Mechanism of Action and Pharmacodynamics

Oxycodone acts primarily as a full agonist at central and peripheral $\mu$-opioid receptors, with lesser affinity for $\kappa$– and $\delta$-opioid receptors:

• $\mu$-Opioid Receptor Activation: Binds to G-protein-coupled $\mu$-opioid receptors located on presynaptic and postsynaptic membranes in the central nervous system (brainstem, locus coeruleus, periaqueductal gray) and spinal cord dorsal horn.

• Intracellular Signaling: Inhibits adenylyl cyclase activity, decreases intracellular cyclic AMP ($\text{cAMP}$), hyperpolarizes neuronal membranes via inwardly rectifying potassium channels, and blocks presynaptic voltage-gated N-type calcium channels.

• Analgesic Inhibition: Suppresses the presynaptic release of nociceptive neurotransmitters (substance P, glutamate, calcitonin gene-related peptide), dampening pain signal transmission along spinothalamic pathways and altering central pain perception.

Additional pharmacodynamic effects include central respiratory center depression, sedation, miosis, cough suppression, smooth muscle spasm, reduced gastrointestinal motility, and physical dependence.

3. Approved Clinical Indications and Dosing Scope

Licensing for OxyContin 20 mg includes:

• Severe Chronic Pain: Management of severe pain requiring daily, continuous, long-term opioid treatment where alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are inadequate.

Dosing & Administration Regimen:

• 12-Hour Dosing Interval: Administered orally every 12 hours. Dosing must be individually titrated based on pain severity and prior patient opioid exposure.

• Administration Integrity: Tablets must be swallowed whole with sufficient water and never pre-soaked, crushed, chewed, split, or dissolved. Tampering with the extended-release matrix compromises controlled delivery, leading to rapid drug release (“dose dumping”) and potential fatal overdose.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Exhibits biphasic absorption characteristics with an initial prompt release followed by gradual controlled release over 12 hours. Absolute oral bioavailability ranges from 60% to 87%. Peak plasma concentrations (Cmax​) occur within 3 to 4.5 hours (Tmax​) post-ingestion.

• Distribution: Widely distributed throughout body tissues following systemic absorption (Vd​≈2.6 L/kg). Plasma protein binding is relatively low (~38% to 45%, primarily bound to serum albumin). Crosses the blood-brain barrier and placenta; excreted in human milk.

• Biotransformation: Extensively metabolised in the liver via two main Cytochrome P450 pathways:

  • CYP3A4 Pathway (Major): $N$-demethylation to noroxycodone (a weak opioid agonist).

  • CYP2D6 Pathway (Minor): $O$-demethylation to oxymorphone (a potent, active opioid agonist).

  • Metabolites undergo subsequent Phase II glucuronide conjugation.

• Elimination: Excreted predominantly via the kidneys in urine as conjugated metabolites and unchanged parent compound (< 10%). Apparent elimination half-life (t1/2​) of the extended-release formulation is approximately 4.5 to 8 hours.

5. Physiological Effects and Adverse Event Spectrum

Oxycodone depresses central nervous system processing, slows cardiac/respiratory drive, and delays gastrointestinal transit time.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Constipation, nausea, somnolence, dizziness, headache, pruritus.

• Common ($\ge 1/100$ to $<1/10$): Vomiting, dry mouth, anorexia, abdominal pain, asthenia, fatigue, confusion, anxiety, insomnia, hyperhidrosis, rash.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Respiratory depression, profound sedation, miosis, urinary retention, hallucinations, agitation, euphoria, orthostatic hypotension, physical dependence/withdrawal.

• Rare / Very Rare (<1/1,000): Anaphylactic reactions, paralytic ileus, seizures, opioid-induced hyperalgesia, adrenal insufficiency.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contra-indicaties

• Known hypersensitivity to oxycodone or formulation excipients.

• Significant respiratory depression with hypoxia or hypercapnia.

• Acute severe bronchial asthma or severe chronic obstructive pulmonary disease (COPD).

• Suspected or confirmed paralytic ileus or acute abdomen.

• Moderate to severe hepatic impairment.

Key Drug Interactions

• CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin, Ritonavir, Grapefruit Juice): Significantly increase oxycodone plasma concentrations, elevating the risk of fatal respiratory depression.

• CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, St. John’s Wort): Accelerate clearance, reducing analgesic efficacy and potentially precipitating opioid withdrawal.

• CNS Depressants, Benzodiazepines, & Alcohol: Co-administration markedly increases the risk of profound sedation, respiratory depression, coma, and death.

• Monoamine Oxidase Inhibitors (MAOIs): Caution is required; potential for severe CNS excitation or depression.

Clinical Precautions and Monitoring

• Boxed Warning (Opioid Analgesic Risk): OxyContin exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient risk prior to prescribing and monitor regularly.

• Opioid Naïveté: Higher doses or initiation in non-opioid-tolerant individuals carries a substantial risk of fatal respiratory depression.

• Dependence & Withdrawal: Prolonged therapy produces physical dependence. Abrupt discontinuation precipitates a severe withdrawal syndrome (diaphoresis, anxiety, lacrimation, rhinorrhea, abdominal cramps, myalgia). Tapering schedules must be implemented when stopping treatment.